New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
08:39 EDTCPXXCelator Pharmaceuticals initiates PK/PD clinical study of CPX-351
Celator Pharmaceuticals announced that the first patient has been enrolled in a Phase 2 pharmacokinetic and pharmacodynamics, or PK/PD, study evaluating the effects of CPX-351 Liposome Injection on cardiac repolarization in adult patients with acute hematologic malignancies, including acute myeloid leukemia, or AML, acute lymphoblastic leukemia, or ALL, and myelodysplastic syndrome, or MDS. This study will also include patients with moderate baseline hepatic and renal impairment, extending the range of safety and pharmacokinetic observations to this important group of patients.
News For CPXX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
08:09 EDTCPXXCelator Pharmaceuticals announces LLS accelerates payment for CPX-351 study
Subscribe for More Information
June 24, 2015
09:10 EDTCPXXOn The Fly: Pre-market Movers
Subscribe for More Information
08:08 EDTCPXXCelator Pharmaceuticals to host conference call
Conference call to discuss positive induction response results from phase 3 study of CPX-351 will be held on June 24 at 8:30 am. Webcast Link
07:04 EDTCPXXCelator Pharmaceuticals' Acute Myeloid Leukemia candidate shows positive results
Subscribe for More Information
June 19, 2015
10:00 EDTCPXXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:24 EDTCPXXCelator Pharmaceuticals initiated with a Buy at MLV & Co.
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use